Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 29, 2016. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, in accordance with DTR 3.1.4 R(1)(c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding specific share transactions rather than a financial performance report.
Material Changes
The filing reports a specific increase in the notional allocation of GSK American Depositary Shares (ADSs) on April 28, 2016. This change resulted from the revaluation of the cash element of a notional investment held within the GSK 401(K) plan. The transaction price was $43.36 per ADS.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly details the notification of a connected person's transaction.
Important Facts for Investors
- Transaction Type: Increase in notional allocation of ADSs via the GSK 401(K) plan revaluation.
- Connected Person: Dr K Slaoui (Connected Person of Dr M M Slaoui).
- Volume: 8 ADSs.
- Price: $43.36 per ADS.
- Date of Transaction: April 28, 2016.
- Signatory: Victoria Whyte, Company Secretary.